BREAKING: FDA approves Mirati’s KRAS drug in non-small cell lung cancer

FDA granted accelerated approval to Mirati’s KRAS drug adagrasib, which will be marketed as Krazati. The greenlight comes two days ahead of the expected decision and cements the biotech as the second in the KRAS field behind leader Amgen, maker of the May, 2021-approved Lumakras. The nod is for second-line…

...

Click to view original post